Trial Profile
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTAS
- Sponsors Janssen Research & Development
- 27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium.
- 24 Jan 2024 According to a Johnson & Johnson media release, study design of this trial will be presented at the ASCO GU Symposium (San Francisco, January 25-27).
- 11 Sep 2023 Status changed from not yet recruiting to recruiting.